Anti-angiogenic peptides from the N-terminus of endostatin

An anti-angiogenesis and angiogenesis technology, applied in the direction of specific peptides, connective tissue peptides, peptide/protein components, etc., can solve problems such as the unknown mechanism of endostatin

Inactive Publication Date: 2006-12-06
CHILDRENS MEDICAL CENT CORP
View PDF13 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the mechanism of ac...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-angiogenic peptides from the N-terminus of endostatin
  • Anti-angiogenic peptides from the N-terminus of endostatin
  • Anti-angiogenic peptides from the N-terminus of endostatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0288] Example 1: Identification of a 27 amino acid endostatin peptide that produces antitumor activity

[0289] Overlapping peptides of 24-27 amino acids derived from both mouse endostatin and human endostatin were synthesized (Table 1).

[0290] Table 1. Overlapping Mouse and Human Endostatin Peptides

[0291] name sequence

[0292] mouse peptide

[0293] mP1: HTHQDFQPVLHLVALNTPLSGGMRGIR (SEQ ID NO: 4);

[0294] mP2: MRGIRGADFQAFQQARAVGLSGTFR (SEQ ID NO: 136);

[0295] mP3: TFRAFLSSRLQDLYSIVRRADRGSV (SEQ ID NO: 137);

[0296] mP4: GSVPIVNLKDEVLSPSWDSLFSGSQ (SEQ ID NO: 138);

[0297]mP5: GSQGQVQPGARIFSFDGRDVLRHPA (SEQ ID NO: 139);

[0298] mP6: HPAWPQKSVWHGSDPSGRRLMESY (SEQ ID NO: 140);

[0299] mP7: ETWRTETTGATGQASSLLSGRLLEQ (SEQ ID NO: 141);

[0300] mP8: KAASAHNSYIVLAIENSFMTSFSKKK (SEQ ID NO: 142).

[0301] Human peptide

[0302] hP1 1 HSHRDFQPVLHLVALNSPLSGGMRG 25 (SEQ ID NO: 6)

[0303] hP2 23 MRGIRGADFQ A FQQARAVGLAGTFR 47 (SEQ ID NO: 143)

[0304] hP345TFRA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.

Description

[0001] Declaration of Rights: [0002] This invention was made with government support under grant R0 1CA064481 awarded by the National Institutes of Health. The government has considerable rights in this invention. Background technique: [0003] Endostatin, a proteolytically cleaved fragment corresponding to the 183 amino acid end of collagen 18C, has been the subject of many laboratory studies for its antitumor activity without toxic side effects. (O'Reilly et al. (1997) Cell, 88: 277-285.; Kisker et al. (2001) Cancer Res, 61: 7669-7674; Dhanabal et al. (1999) Cancer Res, 59: 189-197 ; Yoon et al. (1999) Cancer Res, 59:6251-6256; Folkman and Kalluri, (2003) Cancer Medicine, 6th edition, pp. 161-194. Hamilton: B.C. Decker Inc.). Numerous anti-angiogenic activities have been reported for this protein, such as inhibition of endothelial cell proliferation, migration, and angiogenesis. Endostatin also inhibits vascular endothelial growth factor (VEGF)-induced vascular permeabi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/11C07K14/78A61K38/04
Inventor 朱达·福尔克曼卡什·贾瓦赫里安罗伯特·T·T·斯金
Owner CHILDRENS MEDICAL CENT CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap